focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
It's not roller caster any more as mostly its close low. I agree that Hikma fundamentals are strong and diversified business in three categories make it sustainable in difficult times but seems market hate this SP for a while as it's comparatively more low than any other pharma on ftse. Let see if USA NHS development brings any positivity.
I hope this cyclic pressure will pass before I change my mind...To me, this getting longer and my average down is above 1500. I will prefer to have a paper loss for at least a year rather than sell it... My unfortunate part is that I was very optimistic about this company and invested all in Hikma, felt that this is own by CEO very much and he will better care of his family assets unlike other CEO's those just get perks but don't have the attachment to the company.
Is it right that Hikma cannot do much more to support SP? Don't know what information shorters have to keep pressurizing SP. What I feel that I may need to wait for a longer ... don't know when the sentiments will change about pharma and particular for Hikma...